The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Tue., Feb. 9, 4:42 AM

Slide #18. Agile Therapeutics, Inc. Secondary Offering

Company: Agile Therapeutics, Inc. (NASDAQ:AGRX)
Date announced: 1/21/2016
Shares Offered: 5,511,812
Date of Pricing: 1/22/2016
Price Per Share: $6.35
Secondary Offering Details: Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced that it intends to offer and sell $30 million of shares of its common stock, subject to market and other conditions, in an underwritten public offering. Agile Therapeutics intends to grant the underwriters a 30-day option to purchase up to $4.5 million of additional shares of common stock. -updated 1/22 - Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced the pricing of its underwritten public offering of 5,511,812 shares of its common stock at a public offering price of $6.35 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Agile Therapeutics, are expected to be approximately $35 million. In addition, Agile Therapeutics granted the underwriters a 30-day option to purchase up to 826,771 additional shares of common stock at the public offering price, less the underwriting discounts and commissions. All shares in the offering will be sold by Agile Therapeutics.

Agile Therapeutics is a development stage company. Co. is focused on the development and commercialization of prescription contraceptive products. Co.'s key product candidate, Twirla®, also known as AG200-15, is a once-weekly prescription contraceptive patch in Phase 3 clinical development. In addition, Co. is developing a pipeline of other transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle, AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.

AGRX SEC Filing Email Alerts Service

Open the AGRX Page at The Online Investor »

Company Name:  Agile Therapeutics Inc
Website:  www.agiletherapeutics.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding AGRX:  13
Total Market Value Held by ETFs:  $1.56M
Total Market Capitalization:  $139.00M
% of Market Cap. Held by ETFs:  1.12%
 

Open the AGRX Page at The Online Investor (in a new window) »

February 9, 2016    4:42 AM Eastern
Quotes delayed 20 minutes



Strong Buy (4.00 out of 4)
97th percentile
(ranked higher than approx. 97% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2016, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.